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DRSP’s reliability and responsiveness was also assessed. RESULTS: Studies showed 
women with PMDD experience severe physical and emotional symptoms at the luteal 
stage of the menstrual cycle (ﬁve days before menses), primarily as a result of hormonal 
ﬂuctuations associated with ovulation. Physical symptoms include: aches/pains; breast 
tenderness/swelling; bloating; weight gain; increased appetite/cravings; sleep problems; 
fatigue and difﬁculties concentrating. Emotional symptoms include: mood swings; 
depressed mood; anxiety/tension; anger; irritability; decreased interest; and feelings of 
being overwhelmed. The experience of these symptoms contributes to functional 
impairment in women with PMDD, particularly in terms of: social functioning; work/
school functioning; productivity; role functioning; relationships; and activities of daily 
living. A review of DRSP item content revealed all symptoms and impacts of PMDD 
are captured by the DRSP, supporting the face and content validity of the instrument. 
Studies also showed the DRSP to have acceptable internal consistency (Chronbach’s 
alpha q0.7), test-retest reliability (ICC correlations 0.67–0.99) and responsiveness to 
improvements following treatment (effect sizes 0.64 1.71). CONCLUSIONS: PMDD 
is associated with physical and emotional symptoms which can have a signiﬁcant 
impact on patients’ lives. The DRSP is a valid, reliable and responsive patient-reported 
tool for assessing PMDD-related symptoms and their impact. The DRSP could be 
useful for clinicians during general practice, or for clinical trials in identifying PMDD 
populations or the impact during treatment.
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OBJECTIVES: Little is known about preferences for technological developments of 
women undergoing fertility treatments. This study aims to investigate the preferences 
for ovarian stimulating hormone (OSH) therapies of infertile women undergoing 
assisted reproduction, to determine the utility values ascribed to different attributes 
of OSH treatments, and to estimate women’s willingness to pay (WTP) for OSH. 
METHODS: A representative sample of ambulatory patients ready to receive, or 
receiving, OSH therapies for infertility were recruited from seven specialized private 
centers in six Autonomous Communities in Spain. Both WTP and conjoint analysis 
(CA) were used to elicit preferences. Attributes and levels of OSH treatments were 
identiﬁed by literature review and two focus groups with experts and patients. WTP 
valuations were derived by double-bounded (closed-ended) and contingent ranking 
methods. RESULTS: 167 patients [mean age: 36 years (SD 4.2)] were interviewed. 
Most participants (53.9%) had a high education level (university degree), were 
married (77.2%), referred an estimated net income beyond a1500 per month (50.9%) 
and had paid between a501 and a1500 for their most recent hormonal treatment 
(57.6%). In 52% of cases, there was more than one cause of infertility (sperm related 
factors, 31%). Maximum WTP for an OSH treatment was a800 (median) per cycle, 
which exceeds previously reported cost per OSH cycle with combo therapies (a691.65), 
while 75% would pay a1500 or less. 56.8% were willing to pay additional a51–300 
for a 1–2% effectiveness gain. Utility values (CA) showed that effectiveness (37.0) was 
the most valued attribute (costs 24.9; safety 16.5; information sharing with physicians 
13.5). Cost of last OSH cycle and WTP shown positive correlation (r  0.203, p  
0.05). CONCLUSIONS: WTP for OSH therapies exceeds current cost. Additional 
WTP exists for 1–2% effectiveness improvement. Effectiveness and costs were the most 
important determinants of preferences, followed by safety and information sharing 
with physicians.
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OBJECTIVES: To investigate drug use six months before (SMBP) and during preg-
nancy (DP) among Serbian pregnant women (SPW). METHODS: Pharmacy based 
cross-sectional survey was conducted among SPW between March through April 
2009. Specially designed questionnaire was used for collecting data on socio-demo-
graphics, health status, and drug (Rx and over the counter) use. Vitamin and iron 
supplements were not included in the analysis. RESULTS: 260 SPW completed the 
questionnaire. 69.6% of SPW were 25–34 years old, 75.8% lived in the city area, the 
majority were high school or college graduates, and 55.4% were pregnant with their 
ﬁrst child. 9.4% of SPW had a chronic disease. There was not a statistically signiﬁcant 
decrease in the percentage of SPW taking drugs DP compared to SMBP (53.9% and 
53.0%, respectively), as well as in an average number of drugs taken (1.54 o 0.73 and 
1.45 o 0.66 drugs/women, respectively (range 1 to 4 before and during pregnancy)). 
The most frequently used drug classes by SPW were: analgetics/antipyretics, hormones, 
antiinfectives, tocolitics and anti-hypertensives (25.5%, 25.5%, 19.7%, 13.7%, and 
7.3%, respectively). The most frequently used analgetic/antipyretic was paracetamol 
(62.83%), while the most frequently used anti-infectives were penicillins and cepha-
losporins (77.0%). The only used tocolitics were fenoterol and hexoprenaline and the 
only used hormones were dydrogesterone and progesterone. Drugs that were used 
belonged to these FDA fetal risk categories B, C, and D (diazepam, alprazolam and 
diclofenac in the 3rd trimester) (52.6%, 26.3%, and 15.8% respectively). SPW did not 
use drugs in the FDA category X. Before pregnancy folic acid usage was low (5.5% 
PW) while during the 1st, 2nd and 3rd trimester of pregnancy usage was 69.96%, 
15.05%, 5.93%, respectively. CONCLUSIONS: Differences in drug use DP and 
SMBP among SPW was negligible. The most frequently used drug classes during 
pregnancy were: analgetics/antipyretics, hormones, antiinfectives, tocolitics and 
antihypertensives.
PIH35
THE APPLICATIONS OF GEOGRAPHIC INFORMATION SYSTEM TO 
QUALITY OF LIFE STUDIES: USING TAIWAN AS AN EXAMPLE
Yang JJ1, Yao G2
1National Taiwan University, Taipei, Taiwan, Taiwan, 2National Taiwan University, Taipei, 
Taiwan
OBJECTIVES: The comparison among diverse regions and populations is one of the 
important issues on the study of quality of life (QoL). This study demonstrated that 
how Geographic Information System (GIS) can help us on the study of QoL. By 
mapping the QoL scores and objective QoL-related data on regional maps, GIS help 
us to interpret the QoL data more intensively. METHODS: The QoL data was col-
lected from the 2001 National Health Interview Survey (NHIS) in Taiwan. 13,010 
participants were randomly selected to complete the WHOQOL-BREF (Taiwan 
version). Mean scores of the four QoL domains were used for each of the 25 admin-
istrative divisions. This study also collected 41 objective QoL-related variables for 
each of the divisions from the 2001 National Statistics. The variables include the facets 
of demography, public security, medical resource, welfare, level of education, occupa-
tion structure, ﬁnancial state, and environment. All variables were illustrated on the 
map of Taiwan by GIS with gradient colors. The correlation coefﬁcients between QoL 
domain scores and these objective variables were also calculated. RESULTS: Based 
on the correlation coefﬁcients, no signiﬁcant correlation was found between psycho-
logical domain score and the objective variables. Four, three, and eleven variables were 
statistically correlated with physical, social, and environmental domain scores respec-
tively. In comparisons of the GIS maps between QoL and the objective variables, 
interpretation on the QoL distribution became easier. In general, QoL decreased from 
northwest to southeast. The signiﬁcant correlation coefﬁcients indicated that ﬁnancial 
state, occupation structure and level of education were comparatively related to QoL 
which were conﬁrmed by the GIS maps. CONCLUSIONS: In this study, we demon-
strate the GIS technology can be an assistant to study the regional distribution of QoL. 
Moreover, objective QoL-related variables can be combined to interpret the QoL dis-
tribution intensively. This approach may be beneﬁcial for policy making.
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OBJECTIVES: POSSIBLE EU® is an ongoing, prospective observational study explor-
ing the experience of postmenopausal women receiving bone loss medications in 
Europe. We previously reported that these women had substantially impaired HRQoL. 
This baseline analysis identiﬁes potential important predictors of HRQoL in these 
women. METHODS: A total of 3402 women were enrolled in 3 treatment cohorts: 
established (treated q1 year), inception (initiating) or switching treatment. Clinical 
data and HRQoL (including EQ-5D) were collected at baseline (N  3011). A multi-
variable analysis model was ﬁtted to identify determinants of EQ-5D score. The linear 
relationship of each variable was assessed using a forward selection process (entry 
level 0.05). The non-linear relationship of the selected variables with the outcome, 
were assessed using natural logarithmic and cubic spline transformations Analyses 
were performed using SAS software, version 9.1 and GNU R. RESULTS: For the full 
analysis set, median age (Q1, Q3) was 69 (61, 76) years; women had a median of 3 
ongoing comorbid conditions at baseline. A high proportion of patients had hyperten-
sion (44%), ongoing back pain (41%), osteoarthritis (34%) hyperlipidaemia (32%), 
ongoing upper GI issues (18%), prior vertebral fractures (13%), and depression 
(13%). For the 3011 patients, 12 variables were signiﬁcantly associated with EQ-5D 
score, explaining 39.4% of the residual variance (Table). CONCLUSIONS: In Euro-
pean women who are receiving/initiating bone loss medication, any prior vertebral 
fracture, ongoing depression, fear of falling, number of ongoing comorbid conditions, 
upper GI issues and back pain are prevalent, and strongly predictive, of lower HRQoL. 
Table: Determinants of EQ-5D utility [0 to 1 continuous score]: The effects are 
 Intercept: 0.1801, 0.1083, 0.486, 0.2195; Inception vs. Established*: 0.04862, 
0.06822, 0.02903, .0001; Switch vs. Established*: 0.01271, 0.03901, 0.01360, 
0.3435; Lack of fear of falling: 0.00545, 0.005092, 0.005808, .0001; Ongoing 
depression: 0.1076, 0.1345, 0.08076, .0001; Any prior vertebral fractures: 
0.09239, 0.1225, 0.06223, .0001; Number of ongoing comorbid conditions: 
0.01122, 0.01773, 0.00471, 0.0007; Ongoing upper GI (GERD, reﬂux, dyspep-
sia): 0.04067, 0.06549, 0.01586, 0.013; Ongoing back pain: 0.03455, 0.05594, 
0.01316, 0.0016; BMI: 0.00298, 0.0049, 0.00105, 0.0024; Ongoing seizure 
